Home
|Insights
|Apotex Challenges Amgen Cancer Biologic Patent As Obvious

PDF Link

Apotex Challenges Amgen Cancer Biologic Patent As Obvious

Press Coverage | 12.13.17

Attachments

Download Attachment
20171213 Apotex Challenges Amgen Cancer Biologic Patent As Obvious

Contacts

Michael H. Jacobs
Partner
- Washington, D.C.
  - D | +1.202.624.2568
bWphY29ic0Bjcm93ZWxsLmNvbQ==
Deborah H. Yellin
Partner
She/Her/Hers
- Washington, D.C.
  - D | +1.202.624.2947
ZHllbGxpbkBjcm93ZWxsLmNvbQ==
Shannon Lentz
Partner
She/Her/Hers
- Washington, D.C.
  - D | +1.202.624.2897
c2xlbnR6QGNyb3dlbGwuY29t

Insights

Press Coverage | 04.25.25

Crowell & Moring Adds AI Partner

Press Coverage | 04.25.25
How HR Can Improve Credibility Determinations In Investigations
Press Coverage | 04.25.25
Prada Acquires Versace; INTA Publishes Greenwashing Report; Rightmove Challenges Right Room – News Digest
Press Coverage | 04.24.25
Challenges Of The Amended Form PF June 12, 2025, Compliance Deadline

View All Insights

Subscribe

to the latest insights from our team